Log in

NASDAQ:SURFSurface Oncology Stock Price, Forecast & News

+0.35 (+6.22 %)
(As of 08/5/2020 04:00 PM ET)
Today's Range
Now: $5.98
50-Day Range
MA: $5.53
52-Week Range
Now: $5.98
Volume1.09 million shs
Average Volume1.07 million shs
Market Capitalization$169.37 million
P/E RatioN/A
Dividend YieldN/A
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Surface Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SURF



Sales & Book Value

Annual Sales$15.36 million
Book Value$2.03 per share


Net Income$-54,790,000.00


Market Cap$169.37 million
Next Earnings DateN/A
OptionableNot Optionable
+0.35 (+6.22 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SURF News and Ratings via Email

Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Surface Oncology (NASDAQ:SURF) Frequently Asked Questions

How has Surface Oncology's stock been impacted by COVID-19 (Coronavirus)?

Surface Oncology's stock was trading at $2.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SURF stock has increased by 152.3% and is now trading at $5.98.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Surface Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Surface Oncology

How were Surface Oncology's earnings last quarter?

Surface Oncology Inc (NASDAQ:SURF) announced its earnings results on Tuesday, May, 12th. The company reported $0.74 EPS for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.31. The business had revenue of $38.59 million for the quarter, compared to analyst estimates of $38.59 million. Surface Oncology had a negative return on equity of 38.44% and a negative net margin of 70.90%.
View Surface Oncology's earnings history

What price target have analysts set for SURF?

2 brokerages have issued twelve-month price targets for Surface Oncology's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Surface Oncology's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 50.5% from the stock's current price.
View analysts' price targets for Surface Oncology

Has Surface Oncology been receiving favorable news coverage?

News headlines about SURF stock have trended negative on Thursday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Surface Oncology earned a news impact score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Surface Oncology

Are investors shorting Surface Oncology?

Surface Oncology saw a drop in short interest in July. As of July 15th, there was short interest totaling 428,700 shares, a drop of 47.2% from the June 30th total of 811,700 shares. Based on an average trading volume of 2,220,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.3% of the shares of the company are short sold.
View Surface Oncology's Current Options Chain

Who are some of Surface Oncology's key competitors?

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Allena Pharmaceuticals (ALNA), Verizon Communications (VZ), Enterprise Products Partners (EPD), Alteryx (AYX), Netflix (NFLX), Vertex Pharmaceuticals (VRTX), Xilinx (XLNX), Carnival (CCL), Enphase Energy (ENPH) and Pfizer (PFE).

Who are Surface Oncology's key executives?

Surface Oncology's management team includes the following people:
  • Mr. Daniel S. Lynch, Exec. Chairman (Age 61)
  • Mr. J. Jeffrey Goater, CEO, Pres & Director (Age 44)
  • Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)
  • Dr. Robert W. Ross, Chief Medical Officer (Age 45)
  • Ms. Jessica Fees, Sr. VP of Fin. & Bus. Operations and Treasurer (Age 47)

When did Surface Oncology IPO?

(SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI acted as the underwriters for the IPO.

What is Surface Oncology's stock symbol?

Surface Oncology trades on the NASDAQ under the ticker symbol "SURF."

Who are Surface Oncology's major shareholders?

Surface Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Quantitative Systematic Strategies LLC (0.08%), Cornerstone Investment Partners LLC (0.07%) and Assenagon Asset Management S.A. (0.06%).
View institutional ownership trends for Surface Oncology

Which major investors are buying Surface Oncology stock?

SURF stock was purchased by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC, Cornerstone Investment Partners LLC, and Assenagon Asset Management S.A..
View insider buying and selling activity for Surface Oncology

How do I buy shares of Surface Oncology?

Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Surface Oncology's stock price today?

One share of SURF stock can currently be purchased for approximately $5.98.

How big of a company is Surface Oncology?

Surface Oncology has a market capitalization of $169.37 million and generates $15.36 million in revenue each year. The company earns $-54,790,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Surface Oncology employs 76 workers across the globe.

What is Surface Oncology's official website?

The official website for Surface Oncology is www.surfaceoncology.com.

How can I contact Surface Oncology?

Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.